Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> AMGEN Latest News

SEP 26, 2014 - TheStreet

A Must Read - Share

'Fast Money' Recap: How to Trade After the Market's Drop

NEW YORK (TheStreet) -- The U.S. equity market is having its worst week since July, withathe S&P 500 down 1.62% and the Nasdaq offa1.94% Thursday.a On CNBC's "Fast Money" TV Show, Pete Najarian, co-founder of optionmonster.com and trademonster.com, notedathe financial and technology sectors, which have been pretty strong the past few sessions, took a beating on Thursday. If stocks like ...

Tags: 'Fast Money' Recap: How to Trade After the Market's Drop,  Amgen Latest News

SEP 25, 2014 - TheStreet

A Must Read - Share

'Fast Money' Recap: What Market? The Focus Remains on Apple

a NEW YORK (TheStreet) -- The S&P 500 was able to rally on Wednesday, closing upa0.78%.a However, the trading panel on CNBC's "Fast Money" TV show discussed Apple instead, which fell 1% on the day after the company announced it will discontinue its iOS 8 update for the time being.a Guy Adami, managing director of stockmonster.com, thinks the stock is ...

Tags: 'Fast Money' Recap: What Market? The Focus Remains on Apple,  Amgen Latest News

SEP 24, 2014 - Zacks Investment Research

A Must Read - Share

SEP 23, 2014 - Zacks Investment Research

A Must Read - Share

Amgen Files Blinatumomab Marketing Application in U.S. - Analyst Blog

Amgen (AMGN) announced that it has submitted a Biologics License Application to the FDA for blinatumomab.

Tags: Amgen Files Blinatumomab Marketing Application in U.S. - Analyst Blog,  Amgen Latest News

SEP 22, 2014 - Benzinga

A Must Read - Share

Amgen Submits Biologics License Application For Investigational BiTE Immunotherapy Blinatumomab

Amgen (NASDAQ: AMGN) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval for its investigational bispecific T cell engager (BiTEĀ®) antibody construct, blinatumomab.

Tags: Amgen Submits Biologics License Application For Investigational BiTE Immunotherapy Blinatumomab,  Amgen Latest News